G Walter Ii Loewenbaum Net Worth

The estimated Net Worth of G Walter Ii Loewenbaum is at least $103 million dollars as of 4 August 2020. G Loewenbaum owns over 50,000 units of 3D Systems stock worth over $986,466 and over the last 20 years G sold DDD stock worth over $102,420,532.

G Loewenbaum DDD stock SEC Form 4 insiders trading

G has made over 140 trades of the 3D Systems stock since 2004, according to the Form 4 filled with the SEC. Most recently G sold 50,000 units of DDD stock worth $1,951,000 on 4 August 2020.

The largest trade G's ever made was selling 800,000 units of 3D Systems stock on 15 May 2013 worth over $32,000,000. On average, G trades about 21,243 units every 30 days since 2004. As of 4 August 2020 G still owns at least 450,441 units of 3D Systems stock.

You can see the complete history of G Loewenbaum stock trades at the bottom of the page.

What's G Loewenbaum's mailing address?

G's mailing address filed with the SEC is 12212 TECHNOLOGY BOULEVARD, , AUSTIN, TX, 78727.

Insiders trading at 3D Systems

Over the last 14 years, insiders at 3D Systems have traded over $140,581,615 worth of 3D Systems stock and bought 532,605 units worth $6,075,291 . The most active insiders traders include G Walter Ii Loewenbaum, Abraham N Reichental et Vyomesh Joshi. On average, 3D Systems executives and independent directors trade stock every 25 days with the average trade being worth of $60,930. The most recent stock trade was executed by Thomas W Erickson on 28 November 2023, trading 50,000 units of DDD stock currently worth $265,000.

What does 3D Systems do?

3d systems provides the most advanced and comprehensive 3d digital design and fabrication solutions available today, including 3d printers, print materials and cloud-sourced custom parts. its powerful ecosystem transforms entire industries by empowering professionals and consumers everywhere to bring their ideas to life using its vast material selection, including plastics, metals, ceramics and edibles. 3ds’ leading personalized medicine capabilities save lives and include end-to-end simulation, training and planning, and printing of surgical instruments and devices for personalized surgery and patient specific medical and dental devices. its democratized 3d digital design, fabrication and inspection products provide seamless interoperability and incorporate the latest immersive computing technologies. 3ds’ products and services disrupt traditional methods, deliver improved results and empower its customers to manufacture the future now.

Complete history of G Loewenbaum stock trades at Luminex Corp et 3D Systems

3D Systems executives and stock owners

3D Systems executives and other stock owners filed with the SEC include:

• Herbert Koeck,
  Executive Vice President, Global Go To Market
• Andrew Johnson,
  Executive Vice President, Chief Legal Officer and Secretary
• Dr. Jeffrey A. Graves,
  Pres, CEO & Director
• Reji Puthenveetil,
  Exec. VP of Industrial Solutions
• Charles Hull,
  Chief Technology Officer, Executive Vice President, Director
• Menno Ellis,
  Exec. VP of Healthcare Solutions
• Andrew Martin Johnson,
  Exec. VP, Chief Legal Officer & Sec.
• Charles McClure,
  Independent Chairman of the Board
• Thomas Erickson,
  Independent Director
• William Curran,
  Independent Director
• Kevin Moore,
  Independent Director
• John Tracy,
  Independent Director
• William Humes,
  Independent Director
• Jeffrey Wadsworth,
  Independent Director
• Jimmy Kever,
  Independent Director
• Malissia Clinton,
  Independent Director
• Anthony Grabenau,
  Principal Accounting Officer
• Sadie Stern,
  Executive Vice President - People and Culture
• Reji Puthenveetil,
  Executive Vice President - Industrial Solutions
• Radhika Krishnan,
  Executive Vice President - Software and Healthcare
• Menno Ellis,
  Executive Vice President - Healthcare Solutions
• Jagtar Narula,
  Chief Financial Officer, Executive Vice President
• Jeffrey Graves,
  President, Chief Executive Officer, Executive Director
• Phyllis B. Nordstrom,
  Exec. VP, Chief People & Culture Officer and Chief Compliance Officer
• John E. Nypaver Jr.,
  VP of Investor Relations & Treasurer
• Dr. Brent Stucker Ph.D.,
  Chief Scientist
• Michael S. Crimmins,
  Sr. VP & Chief Accounting Officer
• Dr. Charles W. Hull,
  Co-Founder, Exec. VP, CTO of Regenerative Medicine & Director
• Jeff Blank,
  Exec. VP of Engineering & Product Devel.
• Allen Latty,
  Sr. VP of People & Culture
• Anthony J. Grabenau,
  VP, Global Corp. Controller & Principal Accounting Officer
• Jagtar Narula,
  Exec. VP & CFO
• Jeffrey D Creech,
  EVP & CFO
• Jim D Kever,
  Director
• John N Mc Mullen,
  EVP & CFO
• Kevin Mcalea,
  Vice President
• G Walter Ii Loewenbaum,
  Director
• Karen E Welke,
  Director
• Mark William Wright,
  EVP & COO
• Vyomesh Joshi,
  President and CEO
• Cathy L Lewis,
  Vice President
• Riper Daniel S Van,
  Director
• Andrew William Banasick Wright,
  SVP, GC & Secretary
• Vasant Padmanabhan,
  Director
• Joseph R. Zuiker,
  EVP, Engineering & Operations
• Philip C. Schultz,
  EVP, Operations
• Theodore A Hull,
  EVP & CFO on 11-11-2014
• Abraham N Reichental,
  President and CEO
• Peter Diamandis,
  Director
• David Robert Styka,
  VP & Chief Accounting Officer
• Damon Joseph Gregoire,
  VP, Chief Financial Officer
• Robert M Jr Grace,
  VP, General Counsel & Secretar
• Todd Booth,
  EVP & Chief Financial Officer
• Michael S Crimmins,
  Former SVP and CAO
• Wayne C Pensky,
  Interim CFO
• Jeff Blank,
  EVP, Engineering and Prod Dev
• David K Leigh,
  EVP & CTO (Additive Mfg)
• Phyllis B Nordstrom,
  EVP & CHRO
• Claudia Drayton,
  Director
• Michael Lynn Turner,
  
• Harriss T Currie,
  President, Regenerative Med
• Margaret E Wicklund,
  Chief Accounting Officer